A landscape of driver mutations in melanoma

Cited by (1,006)

Items 701–800 of 1,006

1. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
   Hildur Helgadóttir, Paola Ghiorzo, Remco van Doorn, Susana Puig, Max Levin, Richard F. Kefford, Martin Lauss, Paola Queirolo, Lorenza Pastorino, Ellen Kapiteijn et al. · 2018 · Journal of Medical Genetics
2. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities
   K. Orlando, Vinh Nguyen, Jesse R. Raab, T. Walhart, B. Weissman · 2019 · Expert Review of Anticancer Therapy
3. Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
   Lavinia Anne Spain, Alexander Coulton, Irene Lobón, Andrew Rowan, Désirée Schnidrig, Scott T.C. Shepherd, Benjamin Shum, Fiona Byrne, Maria Goicoechea, Elisa Piperni et al. · 2023 · Cancer Discovery
4. Oncogenes in melanoma: An update
   Manfred Kunz · 2014 · European Journal of Cell Biology
5. Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
   Shubha Bagrodia, Tod Smeal, Robert T. Abraham · 2012 · Pigment Cell & Melanoma Research
6. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach
   Joshua R. Bradish, Liang Cheng C · 2014 · Human Pathology
7. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma
   Jessamy C. Tiffen, Stephen P. Wilson, Stuart J. Gallagher, Peter Hersey, Fabian V. Filipp · 2016 · Neoplasia
8. Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules
   Klaus Johannes BUSAM, Kara N. Shah, Pedram Gerami, Thomas J. Sitzman, Achim A. Jungbluth, Veronica A. Kinsler · 2016 · The American Journal of Surgical Pathology
9. Prevention of DNA damage in human skin by topical sunscreens
   Catherine M. Olsen, Louise Forsyth Wilson, Adèle C. Green, Neela Biswas, J. Loyalka, David C. Whiteman · 2017 · Photodermatology Photoimmunology & Photomedicine
10. A population genetics perspective on the determinants of intra-tumor heterogeneity
    Zheng Hu, Ruping Sun, Christina N. Curtis · 2017 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
11. Genetic alterations in seborrheic keratoses
    Barbara Heidenreich, Evgeniya Denisova, P. Sivaramakrishna Rachakonda, Onofre Sanmartín, Timo Dereani, Md. Ismail Hosen, Eduardo Nagore, Rajiv Kumar · 2017 · Oncotarget
12. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
    Hildur Helgadóttir, Iara Rocha Trocoli Drakensjö, Ada Girnita · 2018 · Frontiers in Oncology
13. Nucleosome positions establish an extended mutation signature in melanoma
    Alexander J. Brown, Peng Mao, M. Smerdon, John J. Wyrick, Steven A. Roberts · 2018 · PLoS Genetics
14. Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
    Kang-Hoon Lee, Hyeon‐Ji Hwang, Hyun Ji Noh, Tae-Jin Shin, Je‐Yoel Cho · 2019 · Cancers
15. Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
    Taylor Rager, Adam Eckburg, Meet Patel, Rong Qiu, Shahina Gantiwala, Katrina Dovalovsky, Kelly D. Fan, Katie Lam, Claire Roesler, Aayush Rastogi et al. · 2022 · Cancers
16. BRAF V600 mutations and pathological features in Japanese melanoma patients
    Naoya Yamazaki, Ryota Tanaka, Arata Tsutsumida, Kenjiro Namikawa, Hironobu Eguchi, Wataru Omata, Kohei Oashi, Toru Ogawa, Amiko Hayashi, N Nakamura et al. · 2014 · Melanoma Research
17. The Evolution of S100B Inhibitors for the Treatment of Malignant Melanoma
    Kira G. Hartman, Laura E. McKnight, Melissa A. Liriano, David J. Weber · 2012 · Future Medicinal Chemistry
18. A highly recurrent RPS27 5'UTR mutation in melanoma
    Ken Dutton‐Regester, Jared J. Gartner, Rafi Emmanuel, Nouar Qutob, Michael A. Davies, Jeffrey E. Gershenwald, William Allen Robinson, Steven E. Robinson, Steven A. Rosenberg, Richard A. Scolyer et al. · 2014 · Oncotarget
19. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.
    C. G. Chiu, Yoshitaka Nakamura, K. Chong, S. Huang, Neal P. Kawas, T. Triche, D. Elashoff, E. Kiyohara, R. Irie, D. Morton et al. · 2014 · Clinical Chemistry
20. Identification of Metastasis-Suppressive microRNAs in Primary Melanoma
    Douglas Hanniford, Miguel F. Segura, Judy Zhong, Elliot A. Philips, Xavier Jirau-Serrano, Farbod Darvishian, Russell S. Berman, Richard L. Shapiro, Anna C. Pavlick, Brian D. Brown et al. · 2015 · JNCI Journal of the National Cancer Institute
21. Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
    Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, Channing J. Der · 2014 · Clinical Cancer Research
22. Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
    Paolo A. Ascierto, Michael B. Atkins, Carlo Bruno Bifulco, Gerardo Botti, Alistair J. Cochran, Michael A. Davies, Sandra Demaria, Reinhard Dummer, Soldano Ferrone, Silvia Chiara Formenti et al. · 2015 · Journal of Translational Medicine
23. From fish bowl to bedside: The power of zebrafish to unravel melanoma pathogenesis and discover new therapeutics
    Ellen van Rooijen, Maurizio Fazio, Leonard Ira Zon · 2017 · Pigment Cell & Melanoma Research
24. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP
    Rui Wang, Yupeng He, Valerie A. Robinson, Ziping Yang, Paul Hessler, Loren M. Lasko, Xin L. Lu, Anahita Bhathena, Albert Lai, Tamar Uziel et al. · 2018 · Molecular Cancer Therapeutics
25. Enhanced Dendritic Actin Network Formation in Extended Lamellipodia Drives Proliferation in Growth-Challenged Rac1P29S Melanoma Cells
    Ashwathi S. Mohan, Kevin M. Dean, Tadamoto Isogai, Stacy Y. Kasitinon, Vasanth Siruvallur Murali, Philippe Roudot, Alex Groisman, Dana Kim Reed, Erik S. Welf, Sangyoon J. Han et al. · 2019 · Developmental Cell
26. Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
    Lorey K. Smith, Shaghayegh Arabi, Emily J. Lelliott, Grant A. McArthur, Karen E. Sheppard · 2020 · Cancers
27. Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
    Anne Montfort, Florie A. Bertrand, Julia Rochotte, Julia Gilhodes, Thomas Filleron, Jean Milhès, Carine Dufau, Caroline Imbert, Joëlle Riond, Marie Tosolini et al. · 2021 · Cancer Immunology Research
28. Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets
    Alexandros Karagiannakos, Maria Adamaki, Antonis Tsintarakis, Bořivoj Vojtěšek, Robin Fåhræus, Vassilis C. Zoumpourlis, Konstantinos Karakostis · 2022 · Cancers
29. An update on the implications of cyclin D1 in melanomas
    González‐Ruiz, Lucia, González‐Moles, Miguel Ángel, González‐Ruiz, Isabel, Ruiz‐Ávila, Isabel, Ayén, Ángela, Ramos‐García, Pablo · 2020 · Pigment Cell & Melanoma Research
30. Development of EHop-016
    Suranganie Dharmawardhane, Eliud Hernandez O'Farril, Cornelis P. Vlaar · 2013 · The Enzymes
31. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
    M. Ranzani, C. Alifrangis, D. Perna, K. Dutton-Regester, A. Pritchard, Kim Wong, Mamunur Rashid, C. D. Robles-Espinoza, N. Hayward, U. McDermott et al. · 2014 · Pigment Cell & Melanoma Research
32. Kinase gene fusions in defined subsets of melanoma
    Jacqueline A. Turner, Kasey L. Couts, Jamie E. Sheren, Siriwimon Saichaemchan, Witthawat Ariyawutyakorn, Izabela Avolio, Ethan Cabral, M. Glogowska, Carol M. Amato, Steven E. Robinson et al. · 2016 · Pigment Cell & Melanoma Research
33. Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
    Keisha N. Hardeman, Chengwei Peng, B. Bishal Paudel, Christian T. Meyer, Thong Luong, Darren R. Tyson, Jamey D. Young, Vito Quaranta, Joshua P. Fessel · 2017 · Scientific Reports
34. A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants
    Ivana Tichá, Jan Hojny, Romana Michálková, Ondřej Kodet, Eva Krkavcová, Nikola Hájková, Kristýna Němejcová, Michaela Bártů, Radek Jakša, Miroslav Důra et al. · 2019 · Scientific Reports
35. Melanoma Chemoprevention: Current Status and Future Prospects
    Chhabra, Gagan, Ndiaye, Mary Ann, Garcia‐Peterson, Liz Mariely, Ahmad, Nihal · 2017 · Photochemistry and Photobiology
36. Role of miRNA in Melanoma Development and Progression
    Agata Poniewierska-Baran, Sylwia Słuczanowska-Głąbowska, Paulina Małkowska, Olga Sierawska, Łukasz Zadroga, Andrzej Pawlik, Paulina Niedźwiedzka‐Rystwej · 2022 · International Journal of Molecular Sciences
37. Precision Cancer Medicine: The Future Is Now, Only Better
    Apostolia Maria Tsimberidou, Alexander M.M. Eggermont, Richard L. Schilsky · 2014 · American Society of Clinical Oncology Educational Book
38. Mutational status of naevus-associated melanomas
    Danielle Ioshimoto Shitara, Gemma Tell‐Martí, Célia Bádenas, Mílvia M. S. S. Enokihara, Llúcia Alós, Ana Belén Larque, Nílceo Schwery Michalany, J.A. Puig‐Butillé, Cristina Carrera, Josep Malvehy et al. · 2015 · British Journal of Dermatology
39. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
    Fade Aziz Mahmoud, Bradley D. Shields, Issam Makhoul, Laura Fulper Hutchins, Sara C. Shalin, Alan J. Tackett · 2016 · Cancer Biology & Therapy
40. Chromatin remodeling gene<i>ARID2</i>targets cyclin D1 and cyclin E1 to suppress hepatoma cell progression
    Duan, Yujie, Tian, Ling, Gao, Qingzhu, Liang, Li, Zhang, Wenlu, Yang, Yi, Zheng, Yaqiu, Pan, E, Li, Shengwei, Tang, Ni · 2016 · Oncotarget
41. Sun Exposure and Melanoma, Certainties and Weaknesses of the Present Knowledge
    Mariachiara Arisi, Cristina Zane, Simone Caravello, Chiara Rovati, Arianna Zanca, Marina Venturini, Piergiacomo Calzavara‐Pinton · 2018 · Frontiers in Medicine
42. Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics
    Vijay Sagar Madamsetty, Manash Kumar Paul, Anubhab Mukherjee, Sudip Mukherjee · 2019 · ACS Biomaterials Science & Engineering
43. Melanoma Risk and Melanocyte Biology
    Juliette U. Bertrand, Eirı́kur Steingrı́msson, Fanélie Jouenne, Brigitte Bressac–de Paillerets, Lionel Larue · 2020 · Acta Dermato Venereologica
44. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors
    Elena Alexandrova, Annamaria Salvati, Giovanni Pecoraro, Jessica Lamberti, Viola Melone, Assunta Sellitto, Francesca Maria Rizzo, Giorgio Giurato, Roberta Tarallo, Giovanni Nassa et al. · 2022 · Frontiers in Genetics
45. Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
    Christina Jessen, Julia Katharina Charlotte Kreß, Apoorva Baluapuri, Anita Hufnagel, Werner Schmitz, Susanne Kneitz, Sabine Roth, André Marquardt, Silke Appenzeller, Carsten Patrick Ade et al. · 2020 · Oncogene
46. Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
    Rebecca L. Shattuck-Brandt, Sheau‐Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O’Neal, Rami Nayef Al-Rohil, Caroline A. Nebhan, Vijaya Bharti, Kimberly Brown Dahlman et al. · 2020 · Clinical Cancer Research
47. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
    Richard G. Hodge, Antje Schaefer, Sarah V. Howard, Channing J. Der · 2020 · Critical Reviews in Biochemistry and Molecular Biology
48. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma
    Natasa Broit, Peter A. Johansson, Chloe B. Rodgers, Sebastian Walpole, Felicity Newell, Nicholas K. Hayward, Antonia L. Pritchard · 2021 · Molecular Cancer Research
49. Cohesin mutations in myeloid malignancies
    Johann-Christoph Jann, Zuzana Tóthová · 2021 · Blood
50. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
    Brandon Murphy, Elizabeth M. Terrell, Venkat R. Chirasani, Tirzah J. Weiss, Rachel E. Lew, Andrea M. Holderbaum, Aastha Dhakal, Valentina Posada, Marie Fort, Michael S. Bodnar et al. · 2022 · Nature Communications
51. Selenium for the Prevention of Cutaneous Melanoma
    Pamela B. Cassidy, Heidi Deborah Fain, James Cassidy, Sally Tran, Philip J. Moos, Kenneth M. Boucher, Russell Gerads, Scott R. Florell, Douglas Grossman, Sancy Ann Leachman · 2013 · Nutrients
52. Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation
    Stefanie B. Marquez, Kenneth W. Thompson, Li Lu, David Reisman · 2015 · Frontiers in Oncology
53. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach
    Junfei Zhao, Feixiong Cheng, Yuanyuan Wang, Carlos L. Arteaga, Zhongming Zhao · 2016 · Molecular & Cellular Proteomics
54. Pathology and genomics of pediatric melanoma: A critical reexamination and new insights
    Armita Bahrami, Raymond L. Barnhill · 2017 · Pediatric Blood & Cancer
55. miRNAs, Melanoma and Microenvironment: An Intricate Network
    Gabriele Romano, Lawrence N. Kwong · 2017 · International Journal of Molecular Sciences
56. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics
    Georgina Alexandra Cardama, Daniel F. Alonso, Nazareno González, Julián Maggio, Daniel Eduardo Gomez, Christian Diego Rolfo, Pablo Lorenzano Menna · 2018 · Critical Reviews in Oncology/Hematology
57. MEK inhibitors for the treatment of NRAS mutant melanoma
    S. Sarkisian, D. Davar · 2018 · Drug Design, Development and Therapy
58. Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data
    Wiebke Sondermann, Jochen Sven Utikal, Alexander Heinrich Enk, Dirk Schadendorf, Joachim Klode, Axel Hauschild, Michael Weichenthal, Lars Einar French, Carola Berking, Bastian Schilling et al. · 2019 · European Journal of Cancer
59. Dephosphorylation of cGAS by PPP6C impairs its substrate binding activity and innate antiviral response
    Mi Li, Hong‐Bing Shu · 2020 · Protein & Cell
60. No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
    María Romina Girotti, Grazia Saturno, Paul C. Lorigan, Richard Marais · 2014 · Molecular Oncology
61. Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study
    Rodolfo Chicas-Sett, Juan Zafra, Delvys Rodríguez‐Abreu, Juan Castilla-Martinez, Gretel Benítez, Bárbara Salas-Salas, Samuel Hernández, Marta Lloret, Juan Luis Onieva, Isabel Barragán et al. · 2022 · International Journal of Radiation Oncology*Biology*Physics
62. Tissue prognostic biomarkers in primary cutaneous melanoma
    Mario Mandalà, Daniela Massi · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
63. BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
    Jillian M. Silva, Christina A. Bulman, Martin McMahon · 2014 · Molecular Cancer Research
64. Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
    Stuart J. Gallagher, Jessamy C. Tiffen, Peter Hersey · 2015 · Cancers
65. Clinical and pathological associations of the activating RAC 1 P29S mutation in primary cutaneous melanoma
    Victoria Mar, Stephen Q. Wong, Aleksandra Logan, Trung Van Nguyen, Jonathan Simon Cebon, John William Kelly, Rory S Wolfe, Alexander Dobrovic, Catriona McLean, Grant A. McArthur · 2014 · Pigment Cell & Melanoma Research
66. Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure
    Saverio Candido, Venerando Rapisarda, Andrea Marconi, Grazia Malaponte, Valentina Bevelacqua, Pietro Gangemi, Aurora Scalisi, James Andrew McCubrey, Roberta Maestro, Demetrios A. Spandidos et al. · 2014 · Oncology Reports
67. Critical Assessment of Clinical Prognostic Tools in Melanoma
    Alyson L Mahar, Carolyn C. Compton, Susan Halabi, Kenneth R. Hess, Jeffrey E. Gershenwald, Richard A. Scolyer, Patti A. Groome · 2016 · Annals of Surgical Oncology
68. Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
    Igor Vujic, Martina Sanlorenzo, Rosaura Esteve‐Puig, Marin Vujic, Andrew Kwong, Aaron Tsumura, Ryan M. Murphy, Adrian Moy, Christian Posch, Babak Itzinger-Monshi et al. · 2016 · Oncotarget
69. Autophagic UVRAG Promotes UV-Induced Photolesion Repair by Activation of the CRL4 DDB2 E3 Ligase
    Yongfei Yang, Shanshan He, Qiaoxiu Wang, Fan Li, Mi‐Jeong Kwak, Sally Chen, Douglas O’Connell, Tian Zhang, Sara Dolatshahi Pirooz, Yong-Heui Jeon et al. · 2016 · Molecular Cell
70. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma
    Saeideh Momtaz, Kamal Niaz, Faheem Maqbool, Mohammad Reza Abdollahi, Luca Rastrelli, Seyed Mohammad Nabavi · 2016 · BioFactors
71. Precision medicine driven by cancer systems biology
    Fabian V. Filipp · 2017 · Cancer and Metastasis Reviews
72. Gynecologic melanomas: A clinicopathologic and molecular analysis
    Aaron M. Udager, Nora K. Frisch, Linda Hong, Marina Stasenko, Carolyn M. Johnston, J. Rebecca Liu, May P. Chan, Paul W. Harms, Douglas Randall Fullen, Amy P. Orsini et al. · 2017 · Gynecologic Oncology
73. MaxMIF: A New Method for Identifying Cancer Driver Genes through Effective Data Integration
    Yingnan Hou, Bo Gao, Guojun Li, Zhengchang Su · 2018 · Advanced Science
74. When to apply sunscreen: a consensus statement for Australia and New Zealand
    David C. Whiteman, R. Neale, J. Aitken, L. Gordon, Adèle C. Green, M. Janda, C. Olsen, H. Soyer · 2019 · Australian and New Zealand Journal of Public Health
75. Chemical excitation of electrons: A dark path to melanoma
    Premi, Sanjay, Brash, Douglas E. · 2016 · DNA Repair
76. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
    Alexander Maxwell Menzies, Georgina Venetia Long · 2013 · European Journal of Cancer
77. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
    Meng Wang, Ishani Banik, Alan Hunter Shain, Iwei Yeh, Boris C. Bastian · 2022 · Genome Medicine
78. Current understanding of epigenetics role in melanoma treatment and resistance
    Mohsen Karami Fath, Ali Azargoonjahromi, Asma Soofi, Faezeh Almasi, Shahnaz Hosseinzadeh, Saeed Khalili, Kamran Sheikhi, Saeid Ferdousmakan, Soroor Owrangi, Minoovash Fahimi et al. · 2022 · Cancer Cell International
79. Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
    Simone M. Goldinger, Carla Murer, P. Stieger, Reinhard Dummer · 2013 · European Journal of Cancer Supplements
80. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer
    Diego M. Marzese, Dave S.�B. Hoon · 2015 · Expert Review of Molecular Diagnostics
81. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients
    Carmen Ruiz Velasco, Julia Li, Madelyn S. Luttgen, Anand R. Kolatkar, Jude Kendall, Edna I. Flores, Zheng Zhu Topp, Wolfram E. Samlowski, Edward Francis McClay, Kelly J. Bethel et al. · 2015 · Physical Biology
82. MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations
    Xing Hua, Paula L. Hyland, Jing Li Huang, Lei Song, Bin Zhu, Neil E. Caporaso, Maria Teresa Landi, Nilanjan Chatterjee, Jianxin Shi · 2016 · The American Journal of Human Genetics
83. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression
    Stefan Kraft, María Teresa Fernández‐Figueras, Nina Anika Richarz, Keith T. Flaherty, Mai P. Hoang · 2017 · Journal of the American Academy of Dermatology
84. Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
    Ugo Testa, Germana Castelli, Elvira Pelosi · 2017 · Medical Sciences
85. Medical management of brain metastases
    Adam J. Lauko, Yasmeen Rauf, Manmeet Singh Ahluwalia · 2020 · Neuro-Oncology Advances
86. The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics
    William Giblin, Lauren R. Bringman, Angela H. Guo, Surinder Kumar, Alexander C. Monovich, Ahmed M. Mostafa, Mary E. Skinner, Michelle Azar, Ahmed S.A. Mady, Carolina H. Chung et al. · 2021 · Journal of Clinical Investigation
87. Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks
    Anca Filimon, Iulia A. Preda, Adina F. Boloca, Gabriela Negroiu · 2021 · Cells
88. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth
    Anthony M. Barsotti, Michael Ryskin, Wenyan Zhong, Weiguo Zhang, Andreas Giannakou, Christine Loreth, Veronica Diesl, Maximillian T. Follettie, Jonathon Golas, Michelle Lee et al. · 2015 · Oncotarget
89. Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase
    Laurie G. Hudson, Jennifer M. Gillette, Huining Kang, Melanie R. Rivera, Angela Wandinger‐Ness · 2018 · Cancers
90. Deciphering ligand–receptor-mediated intercellular communication based on ensemble deep learning and the joint scoring strategy from single-cell transcriptomic data
    Lihong Peng, Jingwei Tan, Wei Xiong, Li Zhang, Zhao Wang, Ruya Yuan, Zejun Li, Xing Chen · 2023 · Computers in Biology and Medicine
91. Achievements and Challenges of Molecular Targeted Therapy in Melanoma
    Ryan Joseph Sullivan, Patricia Mucci LoRusso, Scott Anthony Boerner, Reinhard Dummer · 2015 · American Society of Clinical Oncology Educational Book
92. RAC1 and Melanoma
    Ruth Halaban · 2014 · Clinical Therapeutics
93. New therapeutic options for advanced non-resectable malignant melanoma.
    S. Stadler, Kasia Weina, C. Gebhardt, J. Utikal · 2015 · Advances in Medical Sciences
94. Emerging targeted therapies for melanoma treatment (Review)
    ANGELA RUSSO, Bartolomea Ficili, Saverio Candido, Franca Maria Pezzino, Claudio Guarneri, Antonio Biondi, Salvatore Travali, James Andrew McCubrey, Demetrios A. Spandidos, Massimo Libra · 2014 · International Journal of Oncology
95. DNA Sequencing of Cancer: What Have We Learned?
    Juliann Chmielecki, Matthew M. Meyerson · 2013 · Annual Review of Medicine
96. Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
    William M. Lin, David E. Fisher · 2016 · Annual Review of Pathology Mechanisms of Disease
97. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
    William Bruno, on behalf of the Italian Melanoma Intergroup (IMI), Claudia Martinuzzi, Virginia Andreotti, Lorenza Pastorino, Francesco Spagnolo, Bruna Dalmasso, Francesco Cabiddu, Marina Gualco, Alberto Ballestrero et al. · 2016 · Oncotarget
98. Energy metabolism in skin cancers: A therapeutic perspective
    Mohsen Hosseini, Zeinab Kasraian, Hamid Reza Rezvani · 2017 · Biochimica et Biophysica Acta (BBA) - Bioenergetics
99. Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges
    Andrew E. Rodda, Bradyn J. Parker, Andrew G Spencer, Simon R. Corrie · 2018 · ACS Sensors
100. Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling
     Klaus Griewank, Christian Koelsche, Johannes A.P. van de Nes, Daniel Schrimpf, Marco Gessi, Inga Möller, Antje Sucker, Richard A. Scolyer, Michael E. Buckland, Rajmohan Murali et al. · 2018 · Clinical Cancer Research